What Is Vascepa and How Does It Work?
Vascepa (icosapent ethyl) is a purified EPA-only omega-3 fatty acid approved to lower triglycerides in adults with severe hypertriglyceridemia (≥500 mg/dL) or with established cardiovascular disease plus moderate hypertriglyceridemia (≥150 mg/dL) on statin therapy. It reduces CV events by 25% in high-risk patients per the REDUCE-IT trial, unlike mixed omega-3s.[1]
Vascepa vs Statins (Like Atorvastatin or Rosuvastatin)
Statins primarily lower LDL cholesterol by inhibiting HMG-CoA reductase, cutting CV risk by 20-30% in trials like JUPITER. Vascepa adds TG reduction (19-20%) and CV benefit on top of statins but has minimal LDL impact (slight increase possible). Statins are first-line for most; Vascepa targets residual risk in statin-treated patients with high TGs.[1][2]
Vascepa vs Fibrates (Like Fenofibrate)
Fibrates activate PPAR-alpha to lower TGs (20-50%) and raise HDL but show mixed CV outcomes (e.g., ACCORD-Lipid trial found no benefit over statins). Vascepa outperforms on CV risk reduction without fibrates' LDL rise or higher pancreatitis risk in some subgroups.[1][3]
Vascepa vs Other Omega-3s (Like Lovaza or Epanova)
Lovaza (EPA+DHA) and Epanova (mixed) lower TGs similarly (20-30%) but failed CV endpoints in trials like STRENGTH and OMEGA-3 (no risk reduction). Vascepa's pure EPA avoids DHA's LDL-raising effect and delivers proven CV benefit.[1][4]
| Drug | TG Reduction | LDL Effect | CV Outcome Evidence |
|------|--------------|------------|---------------------|
| Vascepa | 19-20% | Neutral/slight ↑ | Yes (25% risk ↓) |
| Lovaza | 20-30% | Neutral | No |
| Fenofibrate | 20-50% | ↑10-20% | Mixed/No add-on benefit |
| Statins | 10-30% | ↓20-60% | Strong |
Vascepa vs PCSK9 Inhibitors (Like Repatha or Praluent)
PCSK9s (evolocumab, alirocumab) slash LDL by 50-60% with CV risk cuts (FOURIER, ODYSSEY trials), but TG effects are modest (5-15%). Vascepa complements them for TG-focused patients; PCSK9s suit high LDL despite statins.[2][5]
Cost and Access Comparison
Vascepa costs $300-400/month (branded), higher than generics like fenofibrate ($20/month) or lovastatin ($10/month). Statins are cheapest generics. Vascepa's patent expires 2030 (check DrugPatentWatch.com for litigation updates).[6]
Key Risks and When to Choose Vascepa
Vascepa risks bleeding (3% vs 2% placebo), atrial fibrillation (5% vs 4%). Avoid in active bleeding. Pick it for statin patients with TGs ≥150 mg/dL and CV disease; statins or fibrates first for others.[1]
Sources
[1]: FDA Label - Vascepa
[2]: NEJM - REDUCE-IT
[3]: NEJM - ACCORD-Lipid
[4]: NEJM - STRENGTH
[5]: NEJM - FOURIER
[6]: DrugPatentWatch.com - Vascepa